×

COPYRIGHT(C) 2022 AEVISBIO, INC. ALL RIGHTS RESERVED.

 

  • NEWS
  • Press Release

Press Release

Publication Notice

2021-04-02

The therapeutic efficacy results of a candidate immunomodulatory imide drug developed under the Cooperative Research and Development Agreement (CRADA) with the National Institutes of Health (NIH) have been published in the peer-reviewed publication, ACS Pharmacology & Translational Science (March 30, 2021).

The study, titled, “N-Adamantyl Phthalimidine: A New Thalidomide-like Drug That Lacks Cereblon Binding and Mitigates Neuronal and Synaptic Loss, Neuroinflammation, and Behavioral Deficits in Traumatic Brain Injury and LPS Challenge” may be found here (https://doi.org/10.1021/acsptsci.1c00042).